In liver cancer, ARID1A mutations occur in all three primary types (HCC, ICC, and cHCC‐ICC) and are associated with clinical characteristics such as tumor size,[54] metastasis, and poor prognosis.[55] As many mutations lead to ARID1A loss of function, ARID1A is generally considered to be a tumor suppressor. The gene discussed is ARID1A; the disease is intrahepatic cholangiocarcinoma.